Form 4: MYGN Director Boosts Stake with Over 100K Shares

Myriad Genetics Director S. Louise Phanstiel acquired over 100,000 shares of common stock in open market purchases, increasing her direct beneficial ownership.

Summary

• S. Louise Phanstiel, a Director of Myriad Genetics Inc. (MYGN), acquired a total of 104,507 shares of common stock through open market purchases.
• The purchases occurred over three consecutive days: 6,100 shares on February 25, 2026, 50,407 shares on February 26, 2026, and 48,000 shares on February 27, 2026.
• The weighted average prices for these transactions were $4.736, $4.803, and $4.661 per share, respectively.
• Following these transactions, Phanstiel's direct beneficial ownership increased to 281,951 shares, with an additional 33,119 shares held indirectly through The Phanstiel Trust.
• The transactions were made pursuant to a Rule 10b5-1(c) plan.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strong positive signal. Significant insider buying by a director suggests confidence in the company's current valuation and future prospects, which is generally well-received by investors.

Positives

• A company director, S. Louise Phanstiel, significantly increased her direct beneficial ownership by acquiring 104,507 shares of common stock.
• Insider buying can signal confidence in the company's future prospects and valuation.
• The purchases were made at an average price range of $4.51 to $5.01, indicating a belief in value at these levels.

Future Outlook

The filing does not contain any forward-looking statements or guidance.

Industry Context

StockSavvy.ai notes that insider buying, particularly by a director, can be interpreted by the market as a positive signal, suggesting that those closest to the company believe its shares are undervalued or that future prospects are strong. In the biotechnology and diagnostics sector, such confidence can be particularly impactful given the long development cycles and regulatory hurdles.

Comparison to Industry Standards

• Insider buying activity is a common occurrence across all industries. While the specific volume of shares acquired by S. Louise Phanstiel is significant for an individual director, it is difficult to compare directly to industry benchmarks without knowing the director's total compensation, the company's market capitalization, or the typical insider buying patterns for comparable companies like Exact Sciences (EXAS) or Guardant Health (GH) in the molecular diagnostics space. However, the consistent buying over three days suggests a deliberate accumulation strategy.

Related Party Transactions

• The transactions involve a director of Myriad Genetics Inc. acquiring shares of the company's common stock, which is a standard insider transaction reported on Form 4.

Stakeholder Impact

• Shareholders may view this insider buying as a positive sign of management confidence, potentially leading to increased investor interest and a positive impact on share price.
• Employees, customers, suppliers, and creditors are not directly impacted by this specific insider trading report, though a positive market reaction could indirectly benefit employee morale or company stability.

Key Dates

Recommendation

The significant insider buying by a director, S. Louise Phanstiel, who acquired over 100,000 shares, indicates strong confidence in Myriad Genetics' current valuation and future outlook. Such a substantial investment by an insider, especially when executed through a Rule 10b5-1 plan, often suggests that the individual believes the stock is undervalued or poised for growth. This action provides a compelling signal for investors to consider a 'buy' position, aligning with the director's conviction.

Keywords

Myriad Genetics, MYGN, insider buying, Form 4, stock purchase, director, beneficial ownership, S. Louise Phanstiel, Rule 10b5-1